沃森生物(300142) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥462,257,650.83, a decrease of 22.93% compared to ¥599,753,563.65 in the same period last year[2] - The net profit attributable to shareholders was ¥2,646,248.58, down 81.27% from ¥14,127,534.12 year-on-year[2] - The basic earnings per share decreased by 80.68% to ¥0.0017 from ¥0.0088 in the same period last year[2] - Net profit for the period was a loss of CNY 19.68 million, compared to a profit of CNY 38.31 million in the previous year, indicating a significant decline[20] - Total operating revenue decreased to CNY 462.26 million from CNY 599.75 million, a decline of approximately 22.9% year-over-year[19] - Total operating costs decreased to CNY 426.65 million from CNY 462.15 million, a reduction of about 7.7% year-over-year[19] Cash Flow - The net cash flow from operating activities was -¥161,674,922.84, representing a decline of 113.87% compared to -¥75,593,431.77 in the previous year[2] - Cash inflow from operating activities totaled $461.36 million, down from $631.85 million year-over-year, reflecting a decrease of approximately 26.9%[22] - Cash outflow from operating activities increased to $623.03 million from $707.44 million, showing a reduction in cash outflow by about 12%[22] - The net cash flow from investment activities was -$69.62 million, an improvement from -$162.35 million in the previous period[22] - Cash outflow for the purchase of fixed assets and intangible assets decreased significantly to $70.45 million from $153.55 million, a reduction of approximately 54%[22] - The net cash flow from financing activities was -$27.35 million, compared to -$14.22 million in the previous period, indicating increased cash outflow[24] - The total cash and cash equivalents at the end of the period stood at $3.50 billion, down from $4.10 billion, reflecting a decrease of about 14.8%[24] - The company received $183,938.75 from financing activities, which is a new cash inflow compared to the previous period[24] - The cash flow from the disposal of fixed assets was $827,624, marking a new source of cash inflow[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥14,364,084,051.45, a decrease of 2.45% from ¥14,724,311,909.25 at the end of the previous year[2] - The company's total assets decreased to CNY 14.36 billion from CNY 14.72 billion, a drop of approximately 2.5%[18] - Total liabilities decreased to CNY 2.88 billion from CNY 3.22 billion, a reduction of about 10.6% year-over-year[18] - The total current assets decreased from CNY 7,066,828,580.51 to CNY 6,748,867,229.30, a reduction of about 4.5%[16] - The total non-current assets amounted to CNY 7.62 billion, slightly down from CNY 7.66 billion, a decrease of about 0.5%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 113,047[10] - The total number of shares held by the top 10 unrestricted shareholders amounts to 44,627,476 shares, with Liu Junhui being the largest shareholder[11] - The top 10 shareholders include major institutional investors, such as China Industrial Bank and E Fund Management, indicating strong institutional support[11] - The company has a significant number of shares under lock-up agreements, with a total of 39,938,290 shares locked due to management restrictions[14] - Liu Yun Chun holds 20,362,636 shares under lock-up, which is part of the management's 75% annual lock-up policy[13] - There are no significant changes in the shareholding structure due to the transfer of shares among the top shareholders[11] Operational Insights - The company reported a significant increase in prepayments by 91.09%, reaching ¥1,967.22 million due to increased procurement and R&D service payments[6] - Other income decreased by 72.34% to ¥671.45 million, primarily due to a reduction in government subsidies received compared to the previous year[8] - The fair value change income was ¥1,413.73 million, a 116.67% increase, attributed to the rise in stock prices of a listed company in Hong Kong[8] - The company has not reported any new product launches or technological advancements during this period[12] - The company reported a significant increase in financial expenses, with a net financial income of CNY -10.77 million compared to CNY -14.80 million in the previous year[20] - Research and development expenses decreased to CNY 66.90 million from CNY 87.02 million, a reduction of approximately 23.2% year-over-year[19] Audit and Compliance - The company has not undergone an audit for the first quarter report, which may affect investor confidence[23]